Overview

Efficacy, Safety And Tolerability Study In Subjects With Parkinson's Disease

Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
The B7441003 study will assess PF-06412562 for motor benefit in Parkinson's disease subjects. Safety, tolerability and PK of PF-06412562 in Parkinson's disease subjects will also be evaluated.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer